Kryštof V - Search Results

1

Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells.

Jorda R, Magar P, Hendrychová D, Pauk K, Dibus M, Pilařová E, Imramovský A, Kryštof V. Jorda R, et al. Among authors: krystof v. Eur J Med Chem. 2020 Feb 15;188:112036. doi: 10.1016/j.ejmech.2020.112036. Epub 2020 Jan 7. Eur J Med Chem. 2020. PMID: 31931341

2

Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.

Otyepka M, Krystof V, Havlícek L, Siglerová V, Strnad M, Koca J. Otyepka M, et al. Among authors: krystof v. J Med Chem. 2000 Jun 29;43(13):2506-13. doi: 10.1021/jm990506w. J Med Chem. 2000. PMID: 10891109

3

Synthesis and biological activity of olomoucine II.

Krystof V, Lenobel R, Havlícek L, Kuzma M, Strnad M. Krystof V, et al. Bioorg Med Chem Lett. 2002 Nov 18;12(22):3283-6. doi: 10.1016/s0960-894x(02)00693-5. Bioorg Med Chem Lett. 2002. PMID: 12392733

4

Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.

Moravcová D, Krystof V, Havlícek L, Moravec J, Lenobel R, Strnad M. Moravcová D, et al. Among authors: krystof v. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2989-92. doi: 10.1016/s0960-894x(03)00631-0. Bioorg Med Chem Lett. 2003. PMID: 12941318

5

2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.

Moravec J, Krystof V, Hanus J, Havlícek L, Moravcová D, Fuksová K, Kuzma M, Lenobel R, Otyepka M, Strnad M. Moravec J, et al. Among authors: krystof v. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2993-6. doi: 10.1016/s0960-894x(03)00632-2. Bioorg Med Chem Lett. 2003. PMID: 12941319

6

8-Azapurines as new inhibitors of cyclin-dependent kinases.

Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M. Havlicek L, et al. Among authors: krystof v. Bioorg Med Chem. 2005 Sep 15;13(18):5399-407. doi: 10.1016/j.bmc.2005.06.007. Bioorg Med Chem. 2005. PMID: 15993080

7

Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.

Dolezal K, Popa I, Krystof V, Spíchal L, Fojtíková M, Holub J, Lenobel R, Schmülling T, Strnad M. Dolezal K, et al. Among authors: krystof v. Bioorg Med Chem. 2006 Feb 1;14(3):875-84. doi: 10.1016/j.bmc.2005.09.004. Epub 2005 Oct 7. Bioorg Med Chem. 2006. PMID: 16214355

8

Synthesis and biological activity of 8-azapurine and pyrazolo[4,3-d]pyrimidine analogues of myoseverin.

Krystof V, Moravcová D, Paprskárová M, Barbier P, Peyrot V, Hlobilková A, Havlícek L, Strnad M. Krystof V, et al. Eur J Med Chem. 2006 Dec;41(12):1405-11. doi: 10.1016/j.ejmech.2006.07.004. Epub 2006 Sep 22. Eur J Med Chem. 2006. PMID: 16996651

9

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M. Krystof V, et al. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740. J Med Chem. 2006. PMID: 17064068

10

Preparation, biological activity and endogenous occurrence of N6-benzyladenosines.

Dolezal K, Popa I, Hauserová E, Spíchal L, Chakrabarty K, Novák O, Krystof V, Voller J, Holub J, Strnad M. Dolezal K, et al. Among authors: krystof v. Bioorg Med Chem. 2007 Jun 1;15(11):3737-47. doi: 10.1016/j.bmc.2007.03.038. Epub 2007 Mar 16. Bioorg Med Chem. 2007. PMID: 17418578

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

155 results

Search Page